Clinical Trials

The ongoing CRUK DETERMINE Trial. DETERMINE is an umbrella-basket platform trial to evaluate licensed targeted therapies in unlicensed indications, in rare adult, paediatric, and teenage/young adult cancers with actionable genomic alterations (including common cancers with rare actionable alterations).

DETERMINE Treatment Arm 04 is evaluating trastuzumab and pertuzumab for adult, paediatric, and teenage/young adult participants with HER2-positive malignancies. Within the Treatment Arm, there is a cohort for eligible participants with eligible patients with salivary gland cancer and ERBB2/HER2 amplification or insertion/indels.

There are currently eight “slots” remaining in this cohort.

The trial is actively seeking salivary gland cancer patients with HER2-positivity (ERBB2/HER2 amplification or insertion/indels).

This is found more commonly in Salivary Duct Carcinoma and Adenocarcinoma NOS (Not Otherwise Specified) but is also found in many others. The DETERMINE trial is open to all types of salivary gland cancer patients - it's the HER2-positivity that is key to taking part.

Find Out More & Share: Please share this information widely within clinical and patient networks. Recruitment is expected to continue until 2027.

DETERMINE For Patients: https://lnkd.in/eXuydBU8

Trial Open: Relief for Dry Mouth (Xerostomia)

We are promoting the AQUAx2 Study, an important clinical trial for patients experiencing persistent dry mouth (xerostomia) following radiotherapy for Head & Neck cancers. Xerostomia significantly impacts quality of life, and this trial is investigating a gene therapy designed to alleviate those symptoms.

• What it is: A Phase II trial investigating a gene therapy (Aquaporin-1) delivered directly to the salivary glands.

• Why it matters: This research is innovative and offers potential hope for long-term symptom relief.

If you or someone you know is suffering from radiotherapy-induced dry mouth, we encourage you to check the eligibility criteria and learn more about the AQUAx2 Study..

Join the trial PRONTO!

We are excited to announce that the pivotal PRONTO trial is officially open for recruitment at The Christie and UCLH, representing a significant step forward in optimising care for Salivary Gland Cancer.

PRONTO is an evaluative study investigating the role of Proton Beam Radiotherapy (PBT) as an adjuvant treatment for patients with localised parotid carcinoma, the most common site for SGC.

Crucially, the primary focus of this study is on patient quality of life: specifically, evaluating whether PBT can significantly reduce the incidence of long-term taste disturbance compared to conventional X-ray radiotherapy.

Any radiotherapy department in England and Wales can now refer eligible patients via the NHS Proton Referral Portal, and we encourage both patients and clinicians to learn more about this vital research aimed at improving survivorship.